BCM
ALNY icon

Brookstone Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Brookstone Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,164
Closed -$204K – 731
2021
Q2 		$204K Buy
+1,164
New +$170K ﹤0.01% 680

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Brookstone Capital Management's ALNY Position: Q3 2021 in Review

Brookstone Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2021, closing a stake of 1,164 shares — an estimated $204K sold.

Brookstone Capital Management first reported a position in ALNY in Q2 2021 and held it in 1 quarter. The position peaked at $204K in Q2 2021. 405 funds tracked by Wall St. Rank hold ALNY as of Q3 2021.

  • Brookstone Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Brookstone Capital Management sold 1,164 Alnylam Pharmaceuticals shares in Q3 2021, an estimated $204K.
  • Brookstone Capital Management first reported a position in Alnylam Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • Brookstone Capital Management's Alnylam Pharmaceuticals position peaked at $204K in Q2 2021.
  • 405 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2021.

Based on Brookstone Capital Management's 13F filing for Q3 2021, filed 3 Nov 2021.